LivaNova Q4 revenue $360.9M (+12.1%); FY25 adj. EPS $3.90; guides FY26 rev. growth 6-7%

LivaNova PLC

2025-FY EPS reported -$4.45 revenue$1,388,053,000

Q4 GAAP EPS $0.56; adjusted EPS $0.86. Full-year revenue $1.39B, +10.7% reported.
Full-year GAAP diluted loss per share $4.45 includes $365.6M SNIA environmental charge.
Full-year adjusted diluted EPS $3.90; adjusted free cash flow $183.3M.
2026 guidance: constant-currency revenue growth 6-7%; adjusted EPS $4.15-$4.25.
CMS increased reimbursement for VNS Therapy DRE procedures effective Jan 1, 2026; FDA approved cloud-based digital health platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.